Go Pro
→ The Pentagon is desperate (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$11.52
+2.7%		$9.53
$2.22
▼
$14.53
$277.33M2.16385,755 shs455,984 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$19.60
-0.1%		$16.72
$5.68
▼
$19.82
$1.26B0.01538,669 shs808,167 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.86
0.0%		$39.65
$9.91
▼
$77.20
$1.07B2.62591,135 shs628 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$22.67
+4.3%		$19.84
$6.67
▼
$28.00
$1.07B1.49852,474 shs525,649 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+4.99%+6.41%+22.20%+12.19%+360.16%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+7.39%+11.85%+8.27%+20.21%+176.87%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+0.07%+0.40%+75.02%+211.72%+631.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.85%+4.68%+6.68%-10.85%+202.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$11.52
+2.7%		$9.53
$2.22
▼
$14.53
$277.33M2.16385,755 shs455,984 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$19.60
-0.1%		$16.72
$5.68
▼
$19.82
$1.26B0.01538,669 shs808,167 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.86
0.0%		$39.65
$9.91
▼
$77.20
$1.07B2.62591,135 shs628 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$22.67
+4.3%		$19.84
$6.67
▼
$28.00
$1.07B1.49852,474 shs525,649 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+4.99%+6.41%+22.20%+12.19%+360.16%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+7.39%+11.85%+8.27%+20.21%+176.87%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+0.07%+0.40%+75.02%+211.72%+631.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.85%+4.68%+6.68%-10.85%+202.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.83
Moderate Buy$39.00238.45% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.63
Moderate Buy$32.1463.98% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.14
Hold$72.50-5.67% Downside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.90
Moderate Buy$51.75128.23% Upside

Current Analyst Ratings Breakdown

Latest ARTV, CGEM, FBRX, and JBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$48.00
8/10/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$45.00 ➝ $47.00
8/10/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$74.00 ➝ $77.00
7/29/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $39.00
7/28/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$74.00 ➝ $77.00
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$77.00
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/21/2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/A$4.48 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$5.00 per shareN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$4.71 per shareN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$83.86M-$3.30N/AN/AN/AN/A-83.31%-70.63%N/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$219.88M-$3.10N/AN/AN/AN/A-52.89%-48.18%N/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$2.02N/AN/AN/AN/A-56.87%-52.74%N/A

Latest ARTV, CGEM, FBRX, and JBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.8785N/AN/AN/AN/AN/A
8/10/2026Q2 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.66-$0.76-$0.10-$0.76N/AN/A
8/6/2026Q2 2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.6251-$0.63-$0.0049-$0.63N/AN/A
8/6/2026Q2 2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7993-$0.81-$0.0107-$0.81$3.67 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
8.16
8.16
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
8.42
8.42
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
2.75
2.75
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
14.29
14.29

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
1.80%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8.60%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.72 million24.27 millionN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3064.36 million58.82 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
513.89 million13.28 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2049.36 million37.98 millionN/A

Recent News About These Companies

Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO
August 12 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-boosts-holdings-in-jade-biosciences-inc-jbio-2026-08-12/
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research
August 11 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jade-biosciences-nasdaqjbio-given-new-7700-price-target-at-btig-research-2026-08-11/
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10 at 2:18 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jade-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate-update-1036435282
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jade-biosciences-inc-nasdaqjbio-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-08-06/
Jade Biosciences (NASDAQ:JBIO) Trading 10% Higher - Here's What Happened
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jade-biosciences-nasdaqjbio-trading-10-higher-heres-what-happened-2026-08-04/
Jade Biosciences (NASDAQ:JBIO) Shares Down 4.2% - Here's What Happened
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jade-biosciences-nasdaqjbio-shares-down-42-heres-what-happened-2026-08-03/
3,105,669 Shares in Jade Biosciences, Inc. $JBIO Acquired by Janus Henderson Group PLC
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3105669-shares-in-jade-biosciences-inc-jbio-acquired-by-janus-henderson-group-plc-2026-08-03/
Jade Biosciences Inc JBIO
August 2, 2026  |  morningstar.comM
Stempoint Capital LP Buys New Stake in Jade Biosciences, Inc. $JBIO
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-buys-new-stake-in-jade-biosciences-inc-jbio-2026-07-30/
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-orbimed-advisors-llc-sells-346152-shares-of-jade-biosciences-inc-jbio-2026-07-27/
Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-affinity-asset-advisors-llc-decreases-holdings-in-jade-biosciences-inc-jbio-2026-07-25/
Jade Biosciences Stock Short Interest Report | NASDAQ:JBIO | Benzinga
July 20, 2026  |  benzinga.comhttps://www.benzinga.com/quote/jbio/short-interest
Jade Biosciences (NASDAQ:JBIO) Shares Down 5.4% - Here's What Happened
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jade-biosciences-nasdaqjbio-shares-down-54-heres-what-happened-2026-07-20/
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jade-biosciences-inc-jbio-stock-132113346.html
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318128/0/en/jade-biosciences-announces-appointment-of-mark-eisner-m-d-m-p-h-to-board-of-directors.html
Jade Biosciences Shareholders Approve Governance and Audit Measures
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/jade-biosciences-shareholders-approve-governance-and-audit-measures?utm_source=marketbeat.com&utm_medium=referral
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jade-biosciences-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-1036229544
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies
June 5, 2026  |  quiverquant.comQ
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/05/3307597/0/en/jade-biosciences-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares.html
Jade Biosciences prices $150M public offering of common stock at $15/share
June 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/jade-biosciences-prices-150m-public-offering-of-common-stock-at-15-share/ar-AA24NOhH
Jade Biosciences Launches Major Underwritten Equity Offering
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/jade-biosciences-launches-major-underwritten-equity-offering?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$11.52 +0.30 (+2.70%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$19.60 -0.03 (-0.14%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$76.86 -0.01 (-0.01%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$22.67 +0.94 (+4.34%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas